Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Study with a Run-in Baseline, Daily Diary Log, and Validated Questionnaires (Greene GCS) with Oral Dietary Supplement
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
TRIPLE
Enrollment
40
Placebo
Dietary supplement containing EstroG-100 and GABA
San Francisco Research Institute
San Francisco, California, United States
RECRUITING24 hour effects following single dose of Mellow Menopause - Hot Flashes
To assess the efficacy for improvement of a treatment product on menopausal vasomotor symptoms (hot flashes- intensity, duration) within 24 hours compared to placebo through daily diary data and MenoLife application based diary.
Time frame: From baseline Day 7 to Treatement Day 1 (Day 8 of study)
Improvement of overall daily menopausal vasomotor symptoms
To assess the efficacy for improvement of overall daily menopausal vasomotor symptoms compared to placebo through daily diary data and MenoLife diary though 7 days. Data in the Daily diary and MenoLife Diary will be compared between the active supplement and placebo groups across different time points.
Time frame: from enrollment to end of study at Day 15
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.